Boston Scientific Corp Says Late-Breaking Post-Market Study Data Reinforce Clinical Procedural Success, Safety Of Acurate Neo Aortic Valve System

Follow us on Google News:
 Boston Scientific Corp Says Late-Breaking Post-Market Study Data Reinforce Clinical Procedural Success, Safety Of Acurate Neo Aortic Valve System
Image source: ©2022 Kalkine Media®

Nov 27 (Reuters) - Boston Scientific Corp:


* LATE-BREAKING POST-MARKET STUDY DATA REINFORCE CLINICAL PROCEDURAL SUCCESS, SAFETY OF ACURATE NEO2™ AORTIC VALVE SYSTEM

* IN EUROPEAN STUDY, PRIMARY SAFETY ENDPOINT OF ALL-CAUSE MORTALITY WAS 0.8% AT 30 DAYS Source text for Eikon: Further company coverage:

Disclaimer

The above content is directly sourced from Reuters under a contractual arrangement. The content is being provided as a convenience and for informational purposes only; and does not constitute an endorsement or approval by Kalkine Media of any of the products, services, or opinions of the organization or individual. The user is apprised that Kalkine Media bears no responsibility for the accuracy, legality, or content of Reuters, any external sites, or for that of subsequent links. The user is requested to contact Reuters directly for answers to questions regarding the content. Please note that Kalkine Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

Featured Articles